CHICAGO, Jan. 14 /PRNewswire/ -- Sword Diagnostics announced today the launch of its proprietary Raman detection system for ultrasensitive immunoassays. The system provides researchers with greater sensitivity which enables more accurate testing of low abundance markers. These increases in performance could aid researchers in basic and clinical science research, drug discovery, and clinical diagnostics development.
“We are pleased with the positive reception our technology has received from the market. The key opinion leaders have found it particularly useful for highly sensitive ELISAs,” said Dave Dingott, founder and CEO of Sword Diagnostics. “The Raman plate reader allows current ELISA users to continue using their 96-well format, making conversion to our technology extremely simple and cost effective.”
Sword markets its technology for biomarker measurement for pharmaceutical drug discovery and academic life science researchers and will partner to develop clinical diagnostics assays. The technical solution is an immunoassay detection system that uses Raman spectroscopy and a proprietary chemistry. The system extends the sensitivity over current detection technologies while being easily incorporated into assays that use a peroxidase-based detection system.
Sword Diagnostics Inc.
